Aug 24, 2026 06:14AM
Apr 24, 2026 08:30AM
Mar 4, 2026 03:00AM
Nov 12, 2025 06:02PM
Nov 4, 2025 04:01PM
Aug 13, 2025 04:31PM
Aug 13, 2025 04:31PM Alvotech (ALVO) Reports 1H EPS of $0.50
Aug 13, 2025 04:15PM
Aug 6, 2025 08:00AM
Aug 6, 2025 08:00AM
May 7, 2025 04:58PM
May 7, 2025 04:45PM
May 2, 2025 08:30AM
May 2, 2025 08:30AM Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
Mar 26, 2025 06:34PM
Feb 24, 2025 08:00AM
Nov 13, 2024 04:05PM
Oct 30, 2024 08:30AM
Aug 15, 2024 04:30PM
Aug 15, 2024 06:15AM
Aug 15, 2024 04:30AM European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Aug 1, 2024 04:01PM
Jul 22, 2024 06:31AM
Jul 22, 2024 06:30AM
Jul 1, 2024 05:46AM
Jul 1, 2024 05:10AM
May 13, 2024 08:00AM
May 13, 2024 08:00AM Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
Apr 16, 2024 05:54PM
Apr 16, 2024 05:43PM
Apr 16, 2024 05:30PM
Mar 5, 2024 04:00PM
Feb 25, 2024 08:36PM
Feb 23, 2024 08:15PM
Feb 23, 2024 08:15PM Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
Nov 28, 2023 04:19PM
Nov 28, 2023 04:15PM
Nov 21, 2023 08:00AM
Aug 22, 2023 09:15AM
Aug 6, 2023 09:00PM
Jul 31, 2023 09:00PM
Jun 30, 2023 09:00PM Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
Jun 19, 2023 09:00PM
May 19, 2023 05:45AM
May 19, 2023 05:00AM
Mar 1, 2023 04:30PM
Feb 27, 2023 07:15PM
Feb 27, 2023 07:15PM
Feb 9, 2023 02:30AM EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
Feb 9, 2023 02:30AM

1,223,010 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All